Highly active novel agents for multiple myeloma aren’t going to bump autologous haematopoietic stem-cell transplantation (aHSCT) from its position as gold standard intensification treatment – yet. An open-label, phase 3 clinical trial of 1,197 adults with newly diagnosed multiple myeloma and fit for high dose, myeloablative chemotherapy randomised patients to single or double aHSCT or ...
HSCT still wins over novel agents for multiple myeloma
By Mardi Chapman
6 May 2020